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and may itself be affected by the choice of insulin delivery device (pen
or vial/syringe). The choice of insulin delivery device may also have
direct effects on effectiveness. Objective: This study aimed to esti-
mate the effects of insulin adherence and delivery device on real-
world health outcomes. Methods: This study included adults with
type 2 diabetes mellitus initiating insulin, with continuous health
plan insurance for 6 or more months before initiation (baseline) and 1
or more year after. Measured outcomes included glycosylated hemo-
globin (Hb A1c) reduction, hospitalization rate, total health care costs,
and pharmacy costs over 1 year of follow-up. Adherence (deﬁned as
having insulin ﬁlls sufﬁcient for the entire quarter), pen or vial/syringe
use, and disease-related patient characteristics were assessed in each
quarter. To account for the time-varying relationship between
adherence, patient characteristics, and outcomes, marginal struc-
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ent combinations of adherence and device choice. Results: Among
the 13,428 patients (mean age 54 years; 46% women; baseline Hb A1c
9.3%), adherent pen users had greater reductions in Hb A1c (0.35%;
P ¼ 0.045), lower hospitalization rates (0.36; P o 0.01), and higher
pharmacy costs ($2923; Po 0.01) than did nonadherent vial users, and
similar total health care costs ($3906 lower; P ¼ 0.1). Pen use and
adherent vial use decreased hospitalization rate and increased phar-
macy but not total costs. Conclusions: Adherence and pen use have
beneﬁcial effects on patients’ real-world outcomes, with the most
favorable effects attributable to adherent pen use.
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Diabetes mellitus is a chronic metabolic disease that affects
approximately 26 million people in the United States [1]. Its
incidence was estimated at 1.9 million cases in the United States
in 2011, and this number is expected to increase rapidly over the
next few decades [1]. Nearly 90% of all cases of diabetes are
classiﬁed as type 2 diabetes mellitus (T2DM) [2]. Current treatment
guidelines for T2DM recommend a stepwise approach to disease
treatment, starting with metformin therapy combined with lifestyle
interventions [3,4]. Insulin therapy is usually recommended for
patients who fail to achieve or to maintain their blood glucose level
target (as measured by glycosylated hemoglobin [Hb A1c] levels)
during the ﬁrst 3 to 6 months after the start of initial treatment, or
for those who have markedly elevated blood glucose levels [5].
A signiﬁcant limiting factor of the real-world effectiveness of
insulin therapy is nonadherence, with more than one third of the
patients with T2DM being poorly adherent [6]. Adherence can bechallenging for patients with T2DM on insulin therapy because
these patients often do not experience immediate consequences
when skipping insulin injections [7]. Other factors inﬂuencing
adherence include lack of time, travel, or public embarrassment
[8]. Nonadherence, however, has been shown to result in serious
clinical and economic consequences [6,7,9].
The choice of insulin delivery system used by patients, such as
syringe/vial or insulin pen, may play an important role in main-
taining insulin adherence, and inﬂuences the clinical and economic
outcomes of insulin treatment. Compared with the traditional
syringe/vial, an insulin pen offers a number of practical advantages,
including greater ease of use, superior accuracy in dosing, greater
social acceptability, and less pain at administration [10]. Conse-
quently, patients frequently report greater satisfaction and develop
treatment preference for pen devices [10–12]. Beyond patient
satisfaction, pen devices may help improve clinical outcomes,
including improvements in insulin adherence [7,10,13,14] and
reductions in Hb A1c levels and hypoglycemic events [13,14].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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options, reductions in hospitalizations and other health care costs
may potentially offset or even lead to decreases in total health care
utilization and costs [7,13–15].
Such improvements in clinical and economic outcomes may be
attributed at least in part to improvements in adherence to insulin
treatment administered with pen devices. Adherence, however,
involves multiple components itself, and pen devices may also
confer advantages beyond improving adherence. In particular,
insulin administration via pen devices may result in more timely
use of insulin, consistent dosing, elimination of errors associated
with incorrect injection techniques, and prevention of other med-
ication errors associated with syringe and vial [16]. All these effects
may also affect the patients’ clinical and economic outcomes.
This study aimed to estimate the causal effect of adherence—
on the basis of prescription reﬁll data—and the effect of using
pen devices versus syringe/vial on annual % Hb A1c changes,
hospitalization rates, pharmacy costs, and total health care costs
in patients with T2DM. To estimate these effects, the following
approaches were adopted.
First, this study assesses treatment types, adherence, and
outcomes longitudinally because they may change over time.
Previous studies have used an intent-to-treat approach, with pen
use or adherence determined during a baseline period and carried
forward through the observation period. This approach will not
capture the impact of real-world treatment decisions, which are
known to change over time in response to patient outcomes. To
account for these changes over time, and to adjust for time-
dependent confounding of the effect of pen use and adherence on
outcomes by patient characteristics, this study uses marginal
structural models (MSMs) [17]. In the longitudinal setting, the
choice of insulin administration device and adherence are affected
by disease indicators and other patient characteristics at previous
time points, which, in turn, affect patient characteristics at later
time points. In this setting, traditional regression adjustment for
baseline characteristics may not yield causally meaningful esti-
mates. When the appropriate assumptions are satisﬁed, however,
MSMs provide reasonable estimates of the causal effects of time-
varying treatments [17–20]. In this article, we focus on the effect of
ﬁxed sequences of adherence and treatment choices. MSMs,
however, have also been used to assess the impact of dynamic
intervention regimes in diabetes, in which the effect of treatment
strategies is evaluated on the basis of patients’ health status
[21,22], and to study mediators in the development of diabetes [23].
Second, previous studies have separately examined the associ-
ations between administration with pen and various outcomes,
whereas this study focuses on the effect of both pen use and
adherence. This allows for ﬁner distinctions of estimates of the
effect of pen device treatment and adherence to treatment to be
drawn than by studying the effect of pen use or of adherence alone.
For example, the model can be used to estimate the effect of pen
use for patients who are not likely to be regular with treatment.
Finally, this study uses a measure of adherence that estimates
the number of days’ worth of insulin recorded in a prescription
ﬁll rather than using the reported days of supply ﬁled in medical
claims [7,24]. Because insulin dosages vary widely between
patients, measuring adherence on the basis of days of supply
reported in claims data may be biased. The measure used in this
article is believed to better reﬂect actual adherence.Methods
Data and Study Sample
This study was a retrospective analysis of administrative medical
claims data from the IMPACT national managed care database,supplemented with laboratory measurements. The database
includes health insurance claims from more than 45 private
and government-sponsored health plans throughout the United
States, and covers claims from January 2001 to December 2010.
The study sample included patients who were diagnosed with
T2DM (International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation [ICD-9-CM] code 250.x0 or 250.x2) and who had at least
one claim for basal insulin (glargine, detemir, or Neutral Prot-
amine Hagedorn insulin). Patients were required to have contin-
uous insurance eligibility for 6 months (baseline period) before
the date of the ﬁrst claim for basal insulin (index date) and for 12
months after the index date (follow-up period). Patients were also
required to have no claims for insulin during the baseline period,
to have at least one claim for an oral antidiabetic drug (OAD) or
glucagon-like peptide 1 (GLP1) agonist in the baseline period (to
ensure that only patients with T2DM were selected for analysis),
and to have at least one recorded measurement of Hb A1c in the
baseline period. Baseline characteristics were examined using
data recorded within 6 months before the index date. These
variables included age at the index date, sex, region, types of
insurance coverage, Hb A1c level, comorbidities (identiﬁed via
ICD-9-CM codes; Charlson comorbidity index [25], microvascular
diseases, hypertension, hyperlipidemia, obesity, and mental ill-
ness [deﬁned by the ICD-9-CM codes 290.xx–311.xx]), number of
OADs, GLP-1 agonist use, concomitant medications, and total and
diabetes-related health care utilization and costs. Baseline Hb A1c
data originated from Hb A1c test levels measured between 6
months before the index date and 15 days after. If patients had
multiple Hb A1c results during this period, the value dated closest
to the index date was used as the baseline value.
Data on each patient’s insulin adherence and insulin device
usage were summarized in four consecutive, nonoverlapping 90-
day intervals (i.e., annual quarters) during the follow-up period.
When deﬁning adherence, using the stated days’ supply on a
prescription ﬁll claim can be problematic with insulin because
dosage depends on various factors, including body weight and
diabetes progression [7]. To account for differences between
stated and actual days of supply, the following data-driven
approach to the estimation of days’ supply of insulin was
adopted. The effective duration of insulin supply for a particular
type of insulin package was determined by examining the interﬁll
times associated with that type of insulin package. Speciﬁcally,
the effective days’ supply associated with each claim was
calculated as the 90th percentile of all interﬁll times reported
for claims with the same metric quantity and insulin product [24].
A dichotomous variable for insulin adherence was deﬁned in
each quarter for each insulin type on the basis of whether the
patient had insulin supply for all days in that quarter. Availability
for all days in a quarter was determined by totaling the effective
days’ supply for all ﬁlls in that quarter. Patients were deﬁned as
adherent in a quarter if they were adherent to at least one type of
insulin. Pen use versus vial and syringe use in each quarter was
determined on the basis of whether the patient exclusively had
claims for insulin pen or for insulin in vial and syringe delivery
format. If the patient had claims for both pen and vial delivery in
a quarter, device use in that quarter was classiﬁed according to
the ﬁrst quarter in a patient’s treatment history in which he or
she did not use both pen and vial and syringe.
The outcomes studied were change in Hb A1c levels, number
of hospitalization events, pharmacy costs, and total health care
costs accumulated over the follow-up period. The change in Hb
A1c levels was calculated as the last measurement of Hb A1c
available in the fourth quarter subtracted from the last available
Hb A1c measurement recorded in the baseline period. Patients
who did not have a measurement of Hb A1c available in the
fourth quarter were excluded from the analysis of this outcome,
with inverse probability of censoring weights applied to account
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identiﬁed by claims for inpatient visits and were summed over
the follow-up period to construct a total count of annual hospital-
izations. Costs were measured as the standardized payment to
the provider allowed by the health plan. Pharmacy costs were
calculated as the sum of costs from pharmacy claims over the
follow-up period. Similarly, total health care costs were calcu-
lated as the sum of costs recorded in medical and pharmacy
claims over the follow-up period. All costs were inﬂation-
adjusted to 2010 USD.
Statistical Analysis
Baseline characteristics of patients selected into the study sam-
ple were summarized descriptively. For this analysis, patients
were classiﬁed into four groups: nonadherent syringe/vial users,
adherent syringe/vial users, nonadherent pen users, and adher-
ent pen users. Patients were classiﬁed as nonadherent versus
adherent on the basis of whether insulin adherence status was
maintained in most of their total available treatment history.
Similarly, patients were classiﬁed as pen versus syringe/vial
users on the basis of whether pen or syringe/vial was used in
most of the quarters in their available treatment history. Con-
tinuous patient characteristics were compared between non-
adherent and adherent patients, as well as between pen users
and syringe and vial users, using Wilcoxon rank-sum tests.
Discrete patient characteristics were compared between the
same groups using chi-square tests.
Separate MSMs for each of the four outcomes were imple-
mented to estimate the effects of insulin adherence and of
administration with pen. The models controlled for both time-
varying covariates and baseline covariates. The following base-
line covariates were controlled for: age, sex, Hb A1c level, GLP1
agonist use, number of OADs, diabetes-related inpatient costs,
diabetes-related emergency room (ER) costs, Charlson comorbid-
ity index, use of beta blockers, use of calcium channel blockers,
use of angiotensin receptor blockers, use of angiotensin-
converting enzyme inhibitors, use of diuretics, use of statins,
mental health comorbidity, mild liver disease, total inpatient
costs, total ER costs, insurance plan, hyperlipidemia, hyperten-
sion, obesity, peripheral vascular disease, and ischemia. TheFig 1 – (A) Causal relationships before weighting. At represents
characteristics at time t, and Y is the outcome. U represents un
treatment. Each At can affect future characteristics L, and each Lt
are shown.) If traditional methods of adjustment are used, contr
of At on Y is biased because the part of the effect of At that pass
controlled for, then the effect of Atþ1 on Y is biased because of c
traditional models are biased. (B) Associations in the reweighte
treatments and measured patient characteristics on current trea
future patient characteristics and outcome unaffected. The unm
effect can be estimated without the bias that arises in the unwetime-varying covariates controlled for were Hb A1c level, number
of OADs, GLP1 use, diabetes-related inpatient costs, diabetes-
related ER costs, use of statins, use of diuretics, use of beta
blockers, use of calcium channel blockers, use of angiotensin-
converting enzyme inhibitors, use of angiotensin receptor block-
ers, retinopathy, neuropathy, nephropathy, total inpatient costs,
and total ER costs. Each MSM was estimated in two stages.
In the ﬁrst stage, we ﬁt logistic regression models to predict
probabilities of pen use and insulin adherence in each quarter as
a function of treatment history and covariates. Predicted proba-
bilities from these logistic regression models were used to form
stabilized inverse probability weights for treatment, with the
following form for each patient [25]:
sw¼ ∏
4
k¼1
_
PðAk¼akjAk1¼ak1,L0¼ l0Þ
∏4k¼1
_
PðAk¼akjAk1¼ak1,Lk1¼ lk1Þ0
ð1Þ
where ak is the treatment and lk includes time-varying patient
covariates (including intermediate outcomes) during the kth
quarter; l0 represents baseline patient characteristics. The treat-
ment history ak1 includes the sequence of treatments up to
quarter k – 1, while the covariate history lk1 includes the
sequence of covariate values up to quarter k – 1, including the
baseline characteristics. Each term in the numerator and denom-
inator is the predicted probability derived from the corresponding
logistic regression. The stabilized weights renormalize the pop-
ulation to remove the effect of prior pen use, adherence, and
patient characteristics on current pen use and adherence in each
quarter, while leaving the effect of pen use and adherence on
future patient characteristics and outcome unaffected (Fig. 1A,B).
When estimating the change in Hb A1c levels, inverse probability
of censoring weights was used to account for missing values of
Hb A1c in the fourth quarter. The stabilized weights for censoring
were similar to those in Equation 1, except that the probability
that Hb A1c was missing in the fourth quarter was modeled
instead. The weights for censoring were multiplied with the
weights for treatment to obtain the ﬁnal weight for each patient.
In the second stage, longitudinal generalized linear models
were ﬁt to populations reweighted by the stabilized weights.
These models included patients’ pen use and insulin adherence
status in each of the four quarters in the follow-up period asboth pen use and adherence at time t, Lt represents patient
measured variables that can affect characteristics but not
can affect future characteristics A. (For clarity, not all arrows
olling for Ltþ1 in regression models, then the estimated effect
es through Ltþ1 is not reﬂected in the estimate. If Ltþ1 is not
onfounding by Ltþ1. Hence, adjusted as well as unadjusted
d population. Reweighting removes the effect of previous
tment at each time, while leaving the effect of treatment on
easured variables do not affect the analysis. Thus, the true
ighted population.
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effects on outcomes. The models used for this set of analyses
were linear regression for Hb A1c change, Poisson regression with
log link for hospitalization counts, and gamma regressions with
log link for both cost outcomes; MSMs are appropriate for these
outcome types (as well as others, such as dichotomous and count
outcomes) [17]. Under the assumptions of no unmeasured con-
founding and correct model speciﬁcation, coefﬁcient estimates
from these models approximate the causal effects of insulin
adherence and of pen use [17]. These models take the general
form
gðE½YjAk¼ak, L0¼ l0Þ¼aþβTakþγTl0 ð2Þ
where g represents the link function and Y represents the
outcome measured over the entire study period. This differs
from the longitudinal repeated-measures model in which Yk,
the outcome during the kth quarter, is modeled on treatments
administered in the same or previous quarters. Model 2 was
chosen because it does not require assumptions about constant
treatment effects over time or lagged treatment effects. To
exhibit the effects of insulin adherence and pen use, the MSMs
were used to predict adjusted mean outcomes under four
representative treatment patterns during follow-up: nonadher-
ence to syringe/vial, adherence to syringe/vial, nonadherence to
pen, and adherence to pen. These patterns assumed that adher-
ence and pen or syringe/vial use remained constant over all four
quarters, although other patterns could have been considered.
Robust standard errors for each of these adjusted means were
obtained and used to generate 95% conﬁdence intervals for the
adjusted means. Wald tests were used to assess signiﬁcant
differences in outcomes for each pair of treatment patterns. All
statistical analyses used a two-sided P value of 0.05 to determine
statistical signiﬁcance.
Analyses were performed using SAS version 9.3 (Cary, NC) and
R version 2.15.1.Results
The study sample included 13,428 patients with T2DM who met
the sample selection criteria. The mean patient age was 54 years,
46% of the patients were women, and the mean baseline Hb A1c
measurement was 9.3%. Signiﬁcant differences in baseline char-
acteristics were observed between nonadherent and adherent
patients and between pen and vial/syringe users (Table 1). Com-
pared with patients nonadherent to insulin, adherent patients
tended to be older, were more likely to be men, had lower health
care utilization and costs, and exhibited differences in previous
medications and comorbidities. Patients who were nonadherent
to syringe/vial had, on average, the lowest pharmacy costs but
also the highest medical costs. Compared with syringe/vial users,
pen users were more likely to be men, had higher pharmacy
costs, but had lower inpatient and ER costs. Higher proportions of
pen users subscribed to point-of-service plans, whereas lower
proportions subscribed to preferred provider organizations, Med-
icare, or Medicaid.
Among patients in the study sample, 4876 patients had a
measurement of Hb A1c recorded during the fourth quarter of
follow-up, and thus were considered for the analysis of Hb A1c
change. Pen users also had slightly greater decreases than did
syringe/vial patients after factoring in insulin adherence status.
Patients who were adherent to pen exhibited marginally sig-
niﬁcantly greater decreases in Hb A1c than did patients who
were nonadherent to syringe/vial (difference in % Hb A1c change
¼ 0.358; P ¼ 0.048). After adjustment for baseline and time-
varying covariates, patients who were adherent to either
syringe/vial or pen had greater mean decrease in Hb A1c frombaseline than did those who were nonadherent to the same type
of device, but the differences were not signiﬁcant (Table 2 and
Fig. 2).
Patients who adhere to treatment using their insulin devices
have signiﬁcantly lower predicted rates of annual hospitaliza-
tions than do nonadherent patients (rate difference ¼ 0.151 per
patient per year [PPPY], P ¼ 0.014 PPPY for syringe/vial; rate
difference ¼ 0.087 PPPY, P ¼ 0.015 PPPY for pen). Pen use also
leads to signiﬁcantly lower hospitalization rates than does
syringe/vial use (rate difference ¼ 0.269 PPPY for nonadherent
users and 0.204 PPPY for adherent users, P o 0.001 for both).
Nonadherent vial delivery of insulin leads to signiﬁcantly higher
rates of hospitalization than for each of the other three treatment
patterns (Table 2 and Fig. 2).
Adjusted mean pharmacy costs were signiﬁcantly higher for
adherent insulin users than for nonadherent insulin users,
averaging an additional $2074 more annually for pen users and
$2923 more annually for vial users (P o 0.001 for both patterns).
Pen users also had higher mean costs than did syringe/vial users,
regardless of adherence status, averaging $574 more annually for
nonadherent users and $849 more annually for adherent users
(P o 0.001 for both).
Both nonadherent and adherent pen users experienced sig-
niﬁcantly lower annual costs than did syringe/vial users (by $4672
for nonadherent users and $5620 for adherent users, Po 0.001 for
both). Comparisons of annual health care costs between adherent
and nonadherent patients using pen or syringe/vial indicated
lower costs for nonadherent patients, but these differences were
not statistically signiﬁcant (Table 2 and Fig. 2).Discussion
This analysis of patients with T2DM used a longitudinal design
and an MSM to identify the causal effects of pen use and
adherence to treatment on glycemic control, hospitalization, total
health care costs, and pharmacy costs studied over a period of 1
year. The analysis indicates that both pen use and treatment
adherence demonstrate beneﬁcial effects on reducing hospital-
izations and lowering total health care costs, produce marginally
signiﬁcant improvements in glycemic control, and lead to an
increase in pharmacy costs. Although pharmacy costs were the
highest for adherent insulin pen users, this was because insulin
pen was more expensive than vial/syringe and adherent patients
consumed more insulin than did nonadherent patients. These
results indicate that patients who are adherent and/or use pen
devices experience fewer hospitalizations, perhaps through
improved glycemic control. Although adherence and pen use
have greater immediate costs (reﬂected in higher pharmacy
costs), the beneﬁts obtained are sufﬁcient to offset these
increased costs, as reﬂected in total health care costs that are
either not signiﬁcantly different (in the case of adherence) or
signiﬁcantly reduced (with pen use). The results also imply that
pen use can have cost-saving beneﬁts that go beyond the beneﬁts
due to improved adherence.
An alternative to the MSM in Equation 2 is to use the
repeated-measures model
gðE½YjAk¼ak, L0¼ l0Þ¼aþβTakþγTl0, ð3Þ
where Yk the outcome is measured in the kth quarter alone rather
than the entire study period, and ak represents treatment in the
kth quarter alone rather than the entire treatment history. Each
model has strengths and weaknesses. MSM 3 is simpler than
MSM 2, and can use information on quarters beyond the fourth
quarter with a manageable number of parameters. However,
MSM 2 makes no assumptions about correlations between quar-
ters, and reduces the need for assumptions about lag in
Table 1 – Summary of baseline characteristics in study sample.
Baseline characteristic Nonadherent,
vial (n ¼ 1,708)
Adherent,
vial (n ¼
5,008)
Nonadherent,
pen (n ¼ 1,120)
Adherent,
pen (n ¼
5,592)
Adherent vs.
nonadherent
Pen
vs.
vial
Demographic characteristic
Age (y), mean  SD 51.9  12.8 54.6  11.1 51.9  11.4 54.5  10.1 o0.001* 0.974
Sex: female, n (%) 909 (53.2) 2,226 (44.4) 565 (50.4) 2,417 (43.2) o0.001* 0.009†
Health care plan, n (%)
HMO 380 (22.2) 1,038 (20.7) 225 (20.1) 1,222 (21.9) 0.954 0.543
POS 691 (40.5) 2,057 (41.1) 588 (52.5) 3,102 (55.5) 0.001† o0.001*
PPO 384 (22.5) 1,255 (25.1) 215 (19.2) 873 (15.6) 0.203 o0.001*
Medicare 227 (13.3) 564 (11.3) 87 (7.8) 365 (6.5) o0.001* o0.001*
Medicaid 20 (1.2) 82 (1.6) 3 (0.3) 21 (0.4) 0.505 o0.001*
Other 6 (0.4) 12 (0.2) 2 (0.2) 9 (0.2) 0.526 0.265
Hb A1c %, mean  SD 9.0  2.4 9.3  2.1 9.4  2.3 9.4  2.0 o0.001* o0.001*
Diabetes-related utilization
and costs, mean  SD
No. of OADs 1.9  0.8 2.2  0.8 2.1  0.8 2.3  0.9 o0.001* o0.001*
GLP1 agonist 68 (4) 291 (5.8) 147 (13.1) 953 (17) o0.001* o0.001*
Diabetes-related inpatient
costs
3,875.5  13,153.2 2,530.3 
10,805.5
1,612.6  6,173.5 1,326.0 
7,817.0
o0.001* o0.001*
Diabetes-related ER costs 172.1  646.2 147.1  719.7 206.1  1,040.8 136.2  681.3 o0.001* o0.001*
Pharmacy costs for
diabetic medications
493.0  674.4 708.8  645.9 649.1  704.9 897.8  803.3 o0.001* o0.001*
All-cause utilization and
costs, mean  SD
All-cause inpatient costs 11,074.4 
30,753.4
6,785.1 
25,644.5
3,996.2  13,434.7 3,552.5 
17,854.3
o0.001* o0.001*
All-cause ER costs 410.8  1,072.8 318.1  1,049.7 409.2  1,515.1 297.3  1,182.4 o0.001* o0.001*
Total pharmacy costs 1,674.9  2,362.7 2,062.8 
2,236.2
2,177.1  4,306.0 2,426.4 
2,528.6
o0.001* o0.001*
Previous medications, n (%)
Beta blockers 363 (21.3) 1,347 (26.9) 236 (21.1) 1,396 (25) o0.001* 0.129
Calcium channel blockers 328 (19.2) 965 (19.3) 215 (19.2) 1,036 (18.5) 0.717 0.376
ARBs 331 (19.4) 1,050 (21) 261 (23.3) 1,447 (25.9) 0.004† o0.001*
ACE inhibitors 590 (34.5) 2,145 (42.8) 409 (36.5) 2,256 (40.3) o0.001* 0.236
Diuretics 377 (22.1) 1,203 (24) 224 (20) 1,141 (20.4) 0.338 o0.001*
Statins 678 (39.7) 2,581 (51.5) 545 (48.7) 3,328 (59.5) o0.001* o0.001*
Charlson comorbidity index,
mean  SD
0.9  1.7 0.7  1.5 0.7  1.5 0.6  1.3 0.010† o0.001*
Comorbidities, n (%)
Mental illness 249 (14.6) 603 (12) 152 (13.6) 741 (13.3) 0.038† 0.298
Mild liver disease 83 (4.9) 240 (4.8) 59 (5.3) 276 (4.9) 0.775 0.654
Hyperlipidemia 950 (55.6) 3,032 (60.5) 747 (66.7) 4,096 (73.2) o0.001* o0.001*
Hypertension 1,063 (62.2) 3,301 (65.9) 743 (66.3) 3,926 (70.2) o0.001* o0.001*
Obesity 205 (12) 454 (9.1) 129 (11.5) 615 (11) 0.009† 0.017†
Peripheral vascular
disease
105 (6.1) 295 (5.9) 57 (5.1) 290 (5.2) 0.7 0.051
Ischemia 294 (17.2) 904 (18.1) 165 (14.7) 845 (15.1) 0.753 o0.001*
Myocardial infarction 77 (4.5) 185 (3.7) 35 (3.1) 129 (2.3) 0.009† o0.001*
Chronic heart failure 171 (10) 470 (9.4) 78 (7) 339 (6.1) 0.044† o0.001*
Peripheral vascular
disease
105 (6.1) 295 (5.9) 57 (5.1) 290 (5.2) 0.7 0.051
Stroke 131 (7.7) 266 (5.3) 50 (4.5) 278 (5) 0.009† 0.010†
Cancer 106 (6.2) 272 (5.4) 64 (5.7) 302 (5.4) 0.236 0.684
HIV 5 (0.3) 22 (0.4) 3 (0.3) 18 (0.3) 0.568 0.471
Nephropathy 86 (5) 225 (4.5) 57 (5.1) 272 (4.9) 0.444 0.486
Neuropathy 158 (9.3) 539 (10.8) 106 (9.5) 593 (10.6) 0.041† 0.968
Retinopathy 182 (10.7) 623 (12.4) 96 (8.6) 545 (9.7) 0.075 o0.001*
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ER, emergency room; GLP1, glucagon-like peptide 1; Hb A1c,
glycosylated hemoglobin; HMO, health maintenance organization; OAD, oral antidiabetic drug; POS, point of service; PPO, preferred provider
organization.
Notes. The baseline period refers to the continuous 6-mo period before the initiation of basal insulin (index date). Patients are classiﬁed as pen
vs. vial patients and adherence status patient groups according to pen use and adherence status in most of the cycles in a patient’s follow-up.
Wilcoxon rank-sum tests were conducted to compare means between adherent and nonadherent patients as well as pen vs. vial patients to
obtain P values for continuous characteristics. Chi-square tests were used for discrete characteristics.
* Signiﬁcant at the 0.05 level.
† Signiﬁcant at the 0.01 level.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 9 8 – 2 0 5 203treatment effect: with MSM 3, we may want to consider alter-
native models such as E½Ykjak, E½Ykjak1, or E½Ykjak,ak1Þ,
whereas MSM 2 incorporates all lagged effects directly.
Associations between use of insulin pen versus syringe/vial
and adherence have been studied previously. Patients consis-
tently show a preference for insulin administration with pen
devices rather than with syringes in studies on patient-reported
outcomes [12,26,27]. Use of pen devices has also been associated
with improvements in medication adherence, reductions in
hypoglycemia episodes, and reductions in health care resource
utilization and costs [13–15]. Adherence to insulin therapy itself
has also been found to be associated with reduced rates of
diabetes-related complications and improved Hb A1c levels
[6,28]. The ﬁndings of this study are consistent with results
published in the previous literature, and support the causality
of conclusions about the effect of adherence on outcomes. In
addition, this study suggests that conclusions about the effect of
adherence on clinical and economic outcomes are valid irrespec-
tive of device type, and vice versa.
This study has several limitations. MSMs depend on the
assumption that all confounders that mediate the relationship
between exposures (i.e., device or adherence level) at two time
points and that affect the ﬁnal outcome are captured in the data
and are appropriately incorporated in the model. Although this
assumption cannot be tested in practice in either cross-sectional
or longitudinal settings [17], this study adds to the literature by
explicitly adjusting for observed time-dependent confounding
variables.
As with any data obtained from an administrative claims
database, these data are subject to measurement error. For
example, variables such as hospitalization counts and comorbid-
ities were calculated on the basis of information from insurance
claims, which may not completely capture patients’ clinical
history.
Patients’ adherence to insulin is particularly challenging to
capture in claims data. Traditional measures of adherence—
such as the medication possession ratio—can perform poorly in
capturing insulin adherence, because almost all claims for
prescriptions of insulin are recorded as a 30-day supply, even
though patients’ insulin needs vary. To address this, we have
used a data-driven approach in calculating the total days of
supply; however, this remains an approximation and may not
capture the true days of supply for individual patients. In
estimating the effect of adherence, we used a stringent dichot-
omous measure, deﬁning insulin adherence as having a 90-day
supply in a 3-month period. Thus, the present study does not
account for variation in adherence among patients with less
than perfect adherence. Further studies may be warranted to
assess the sensitivity of our results to variations in the deﬁni-
tion of adherence. In addition, it is important to assess whether
the assumptions made for this model are valid in other pop-
ulations and whether the effects identiﬁed translate to those
settings.
Despite these limitations, the ﬁndings in this study have
important implications for clinical practice. Although we and
others have shown that pen use improves adherence, the results
from this study clearly indicate that there is variation in the
impact of adherence even among pen users. Thus, improving the
quality of physician-patient communication and counseling
patients about the importance of taking doses in a timely fashion
are important even among pen users. In addition, signiﬁcant
differences in hospitalization and low differences in total costs
between pen users and vial/syringe users indicate that even
patients who are fully adherent may beneﬁt from the use of
pen devices. The mechanisms by which such additional beneﬁts
may be conferred by pen use may include more accurate or
timelier dosing.
Fig. 2 – Adjusted means and conﬁdence intervals for outcomes by treatment pattern. The change in glycosylated
hemoglobin (Hb A1c) levels is the change in %Hb A1c from baseline over the year. Hospitalization rate is expressed in
hospitalizations per person per year. Pharmacy and total costs are reported in dollars during the year. Adjusted means were
calculated from MSMs for each outcome. “Adherent” refers to adherence to insulin in quarters 2, 3, and 4 (all patients are
adherent in quarter 1), while “vial” or “pen” refers to the use of a vial and syringe or a pen device throughout the year. The
MSMs controlled for the following baseline variables: age, sex, Hb A1c level, GLP1 agonist use, number of OADs, diabetes-
related inpatient costs, diabetes-related ER costs, Charlson comorbidity index, use of beta blockers, use of calcium channel
blockers, use of ARBs, use of ACE inhibitors, use of diuretics, use of statins, mental health comorbidity, mild liver disease,
total inpatient costs, total ER costs, insurance plan, hyperlipidemia, hypertension, obesity, peripheral vascular disease, and
ischemia. The MSMs controlled for the following follow-up variables: Hb A1c level, number of OADs, GLP1 use, diabetes-
related inpatient costs, diabetes-related ER costs, use of statins, use of diuretics, use of beta blockers, use of calcium
channel blockers, use of ACE inhibitors, use of ARBs, retinopathy, neuropathy, nephropathy, total inpatient costs, total ER
costs. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ER, emergency room; GLP1, glucagon-like
peptide 1; MSM, marginal structural model; OAD, oral antidiabetic drug. *Po 0.05 when compared with nonadherent vial as
the reference group.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 9 8 – 2 0 5204Conclusions
There is limited information on the effects of insulin adherence
and/or of delivery device on clinical outcomes and health care
costs in T2DM. In this study, insulin administration with a pen
device and improved insulin adherence regardless of device were
found to have separate beneﬁcial effects on glycemic control and
reduce the risk of hospitalization, while not signiﬁcantly increas-
ing total health care costs. These results support investment in
programs that can increase insulin adherence, and support the
hypothesis that pen devices have beneﬁcial effects beyond
improved adherence, when compared with insulin syringe and
vial delivery systems.Acknowledgment
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